Iradimed (NASDAQ:IRMD) Receives “Buy” Rating from Roth Mkm

Roth Mkm reiterated their buy rating on shares of Iradimed (NASDAQ:IRMD) in a research report released on Monday morning, Benzinga reports. Roth Mkm currently has a $65.00 target price on the medical equipment provider’s stock.

Separately, Singular Research restated a buy rating on shares of Iradimed in a report on Monday, April 1st.

Iradimed Trading Down 2.3 %

IRMD opened at $41.47 on Monday. The stock has a market cap of $525.01 million, a price-to-earnings ratio of 30.49 and a beta of 0.82. Iradimed has a 1 year low of $36.12 and a 1 year high of $51.04. The stock has a fifty day moving average price of $42.81 and a 200 day moving average price of $43.01.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.01). The firm had revenue of $17.45 million for the quarter. Iradimed had a net margin of 26.22% and a return on equity of 24.62%. As a group, sell-side analysts forecast that Iradimed will post 1.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Iradimed

Several institutional investors have recently bought and sold shares of the stock. Shaker Investments LLC OH raised its holdings in Iradimed by 1.3% during the first quarter. Shaker Investments LLC OH now owns 20,258 shares of the medical equipment provider’s stock valued at $891,000 after buying an additional 258 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in shares of Iradimed by 73.8% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 8,925 shares of the medical equipment provider’s stock worth $393,000 after purchasing an additional 3,791 shares during the period. Bridge City Capital LLC increased its stake in shares of Iradimed by 23.5% in the first quarter. Bridge City Capital LLC now owns 42,183 shares of the medical equipment provider’s stock worth $1,856,000 after purchasing an additional 8,034 shares during the period. Cim LLC bought a new position in shares of Iradimed in the fourth quarter worth about $449,000. Finally, Ranger Investment Management L.P. increased its stake in shares of Iradimed by 5.4% in the fourth quarter. Ranger Investment Management L.P. now owns 223,612 shares of the medical equipment provider’s stock worth $10,615,000 after purchasing an additional 11,465 shares during the period. 92.34% of the stock is currently owned by institutional investors.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.